Fresh news on health and wellness in Grenada

Provided by AGP

Health Herald Grenada: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Herald Grenada.

Press releases published on May 8, 2026

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
Premier Health Announces Termination of Forbearance Agreements With Principal Lenders and the Continuance of Its Strategic Review Process
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
Azalea Therapeutics Announces Late-Breaking Oral Presentation at ASGCT Annual Meeting Demonstrating First-in-Primate In Vivo TRAC-CAR T Cell Engineering
FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 10, 2026
Invitation à assister à l'assemblée générale annuelle et extraordinaire des actionnaires de la Société qui se tiendra le 10 juin 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TOMI Environmental Solutions, Inc. Reports First Quarter 2026 Financial Results and Announces Transformative Letter of Intent to Merge with Carbonium Core, Inc.
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
James Cacioppo Files Updated Early Warning Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Share us

on your social networks:

Sign up for:

Health Herald Grenada

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.